BTIG analyst Justin Zelin downgraded TScan Therapeutics (TCRX) to Neutral from Buy without a price target following the company’s decision to prioritize its hematologic malignancy program and pause on enrollment in the solid tumor TCR-T study. BTIG now assumes a late-2029 approval for TSC-101. It cites the delay in an expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term share catalysts, for the downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics downgraded to Neutral from Buy at BTIG
- TScan Therapeutics price target lowered to $6 from $9 at Needham
- TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program
- TScan Therapeutics Shifts Focus to Hematologic Malignancies
- TScan Therapeutics to reduce workforce by 30%